Featured Press Releases

Vaxxas begins a Phase I clinical trial for an H7N9 influenza vaccine using its high-density microarray patch (HD-MAP)

Vaxxas begins a Phase I clinical trial for an H7N9 influenza vaccine using its high-density microarray patch (HD-MAP)

GenScript

GenScript's ProBio subsidiary plays a key role in cutting-edge cancer therapies

  • 15 Nov 2024

GenScript Biotech, a global biotechnology leader in the life science, biologics manufacturing,...

Applications Are Being Accepted by the Vilcek Foundation from Immigrants Working in Biomedical Science

Applications Are Being Accepted by the Vilcek Foundation from Immigrants Working in Biomedical Science

Transposon announces Phase 2 results for TPN-101 in treating C9orf72-related ALS and frontotemporal dementia

Transposon announces Phase 2 results for TPN-101 in treating C9orf72-related ALS and frontotemporal dementia

New long-term data confirms TREMFYA® (guselkumab) as the only IL-23 inhibitor proven to block joint damage in active psoriatic arthritis

New long-term data confirms TREMFYA® (guselkumab) as the only IL-23 inhibitor proven to block joint damage in active psoriatic arthritis

Zafrens expands its investor syndicate to scale its revolutionary drug discovery platform

Zafrens expands its investor syndicate to scale its revolutionary drug discovery platform

Tiger BioSciences Launched carePAC™: Pre-Configured Wound Care Kits for Simplified At-Home Management

Tiger BioSciences Launched carePAC™: Pre-Configured Wound Care Kits for Simplified At-Home Management

  • Tiger BioSciences
  • 02 Apr 2026
Thermo Fisher Scientific Unveils Integrated Platform to Enhance Biologics Development

Thermo Fisher Scientific Unveils Integrated Platform to Enhance Biologics Development

  • Thermo Fisher
  • 02 Apr 2026
Orca Bio Announces FDA Extension of BLA Review for Orca-T in the Treatment of Hematologic Malignancies.

Orca Bio Announces FDA Extension of BLA Review for Orca-T in the Treatment of Hematologic Malignancies.

  • Orca Bio
  • 01 Apr 2026
CellCentric Launches DOMMINO-1, a Phase 2 Trial of Inobrodib Combined with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma

CellCentric Launches DOMMINO-1, a Phase 2 Trial of Inobrodib Combined with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma

  • CellCentric
  • 01 Apr 2026
ProductLife Group Appoints Dr. James Burt as CEO

ProductLife Group Appoints Dr. James Burt as CEO

  • ProductLife Group
  • 24 Mar 2026
Constance Sabbagh Appointed as General Manager as Avanzanite Expands French Operations

Constance Sabbagh Appointed as General Manager as Avanzanite Expands French Operations

  • Avanzanite Bioscience B.V.
  • 24 Mar 2026
Drug Discovery 2024
The Digital Pharma Advances Conference 2026

Most Popular
April   2026
M T W T F S S
    1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30      

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.